Mumbai: Pharma major Lupin Limited (Lupin) won the gold award at the 9^th Annual Conference on Quality Management, organised by the American Society for Quality (ASQ) at Ahmedabad on 22 November, 2019. The nomination case study submitted for this award summarised the transformation project to improve the yield and quality of Lupin’s Cefadroxil products.

Speaking on the occasion, Rajendra B Chunodkar, President — Manufacturing Operations, Lupin Ltd. said, “It is a moment of pride. This is the fourth consecutive year that Lupin’s Ankleshwar facility has won the Gold Award from the American Society for Quality. As a leading pharmaceutical company, we have constantly focused our efforts towards enabling manufacturing excellence at all our manufacturing sites. This award highlights and validates our approach toward quality and continuous improvement.”

While, this year Lupin’s nomination highlighted the key outcomes of its “Cefadroxil Yield and Quality Improvement” project, in the past three years, Lupin won the award for projects that focused on Ethambutol Yield Improvement (2018), 7AE Yield Improvement (2017) and 7ACCA Yield Improvement (2016).

About ASQ

ASQ (American Society for Quality) is a knowledge based global community of quality professionals who share the ideas and tools that make our world work better. With millions of individual and organizational members of the community in 150 countries, ASQ has the reputation and reach to bring together the diverse quality champions who are transforming the world’s corporations, organizations and communities to meet tomorrow’s critical challenges. ASQ is headquartered in Milwaukee, Wis., with national service centers in China, India and Mexico. Learn more about ASQ’s members, mission, technologies and training at www.asq.org. 

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8^th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3^rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3^rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6^th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055

For further information or queries please contact:

Arvind Bothra
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com
Ph: +91-22-66408237